We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

Drug Discovery

Drug Discovery

Stay up to date on the topics that matter to you

Trending News

A baby laying down.

No Adverse Health Risks From Steroids Used for Pre-Term Birth, Study Finds

Immunotherapy attacking a cancer cell.

Immunotherapy Combination Approved for Non-Muscle Invasive Bladder Cancer

Two white mushrooms.

Psilocybin Shows Promise for Treatment-Resistant Depression – But Is It Safe?

Phage Therapies for Multidrug-Resistant Infections Should Consider Host Response

First Use of CRISPR-Cas9 Gene Editing in Kissing Bugs

Scientists Uncover the Cellular Functions of Proteins Integral to Inflammatory Diseases

News

Asynt - Leader of the Pack at Lab Innovations 2014

Company wins this year’s Lions’ Lair competition, fighting off competition from three other exhibitors pitching their most innovative products.

Molecular Devices Partners with Roche

Partnership will develop custom Ruthenium Nano-TRF Detection Platform.

Immune Booster Helps Improve Survival In Metastatic Melanoma

Patients with metastatic melanoma who were treated with ipilimumab, an immune checkpoint blocker, survived 50 percent longer – a median 17.5 months vs. 12.7 months – if they simultaneously received an immune stimulant.

ex scientia partners with Sunovion Pharmaceuticals Inc.

Partnership will research new medicines for psychiatric disorders.

Resverlogix Appoints Senior Vice President of Clinical Development

Appointment of Michael T. Sweeney, M.D., as senior vice president.

OGT Initiates Clinical Trial of New Array-Based NIPT

Proprietary microarray technology will be fast, cost-effective, and will enable clinical laboratories to offer NIPT in-house.

Biodesix Announces Inclusion of VeriStrat in Updated NCCN Guidelines

Guidelines provide evidence-based, consensus-driven recommendations for managing cancer.

Genticel: Business Update - Third Quarter 2014

Net cash and equivalents of €35.2 million as of September 30, 2014.

Stellar and Biovest Sign KLH Supply Agreement

Agreement for BiovaxID immunotherapy for follicular non-Hodgkin's lymphoma.

QTS and Hepregen Execute Co-Development and Co-Marketing Agreement

Agreement provides for development, manufacture and sale of HepatoPac® B-CLEAR® co-labeled proprietary products for liver transporter analysis.

Advertisement

Advertisement

Decoratvive background images

Never miss a story

with the Breaking Science News daily newsletter